ARA-290 (cibinetide) is an 11-amino-acid erythropoietin-derived peptide that activates tissue repair without stimulating red-cell production. It has completed human trials in small-fibre neuropathy but is not approved.

Potential. Review the research and limitations before relying on this record.

An 11-amino-acid peptide corresponding to the helix B surface of erythropoietin, which selectively activates the innate repair receptor - a heterodimer of the EPO receptor and the beta-common receptor subunit. This is the key design point: EPO receptor homodimers drive erythroid progenitor maturation, while the heterodimer mediates tissue protection and repair, so ARA-290 separates the repair signal from the erythropoietic one.

Very short plasma half-life of around two minutes, yet sustained biological effects are observed across disease models - the effect outlasts the exposure, consistent with triggering a repair programme rather than requiring continuous receptor occupancy.

No published, curated interaction record is available for this compound in the current library.

ARA-290 has been studied in humans in sarcoidosis-associated small-fibre neuropathy and in type 2 diabetes with neuropathic symptoms, with reported improvements in corneal nerve fibre density and patient-reported neuropathic symptom scores. The trials were small and phase 2; development has not proceeded to approval in any jurisdiction, and the corneal nerve fibre endpoint is a surrogate rather than a clinical outcome.

The defining safety finding is a negative one that worked as designed: unlike full erythropoietin, ARA-290 avoids rises in haematocrit, platelet activation and selectin expression, removing the thrombotic risk that limits EPO use. Human safety data beyond the small phase 2 trials is limited. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.

This is a source-backed summary, not a recommendation. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome. Availability, legal status and product quality differ by jurisdiction; consult a qualified clinician.